Radiotherapy for Oligometastatic Non–Small Cell Lung Cancer: Past, Present, and Future

Historically, patients with stage IV non–small cell lung cancer (NSCLC) have been treated with chemotherapy alone, reserving local therapies for symptom palliation. However, evidence has accumulated that a subset of patients with oligometastatic NSCLC (OM-NSCLC) may benefit from local ablative therapies (LATs). In this article, we review the data that have formed the rationale for LAT, specifically radiotherapy, and the prospective trials that support its use in this population. Finally, we examine the evolving role of LAT in patients with OM-NSCLC in the context of immunotherapy and targeted therapies, as well as discuss ongoing clinical trials incorporating LAT in these patients. READ ARTICLE

ONCOLOGY DOI: 10.46883/onc.2021.3506.0311

Authors: Neal S. McCall and Kristin A. Higgins

Review Paper, group5Kirk SmithJune 17, 2021NSCLC, oligometastatic, stereotactic body radiotherapy, local ablative therapy

The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?

When early-stage metastases appear, what is the evidence comparing the utility of systemic drug treatment versus focused radiation? "Oligoprogressive disease is a relatively new clinical concept describing progression at only a few sites of metastasis in patients with otherwise controlled widespread disease. Local ablative therapy for oligoprogressive disease may allow the continuation of systemic treatments by overcoming the few sub-clones that have developed resistance." READ ARTICLE

Clinical Oncology; DOI: 10.1016/j.clon.2019.05.015;

Authors: P.H. Patel, D. Palma, F. McDonald, A.C. Tree

Review PaperKirk SmithDecember 1, 2019metastatic disease, Oligometastases, oligoprogression, stereotactic body radiotherapy, targeted therapy